semaglutide vs ozempic differences whats the difference between and tirzepatide tirzepatide versus ozempic Tirzepatide, which is better for you? Semaglutide vs Ozempic vs Wegovy

Visit Duane Hampton, NP , and Jeannie Ocasio-Hampton, NP , at Hampton Health Wellness Aesthetics to learn more about how we can help you boost your energy and improve your well-being through personalized care

Beginner's guide to the investigational triple-agonist: what it is, how it works, and what the research shows

Each of the pens delivers different amounts of doses of medication, which can be adjusted depending on personal needs or body weight

Insulin Sensitivity and Beta Cell Function Research revealed improvements in both insulin sensitivity and pancreatic function[13]: Enhanced HOMA-IR scores indicating improved insulin sensitivity Reduced fasting insulin levels despite improved glucose control Preserved or improved beta cell function markers (HOMA-beta, C-peptide) Potential protective effects on pancreatic beta cell mass in preclinical models Cardiovascular and Metabolic Health Research Lipid Profile Improvements Studies documented favorable effects on multiple cardiovascular risk markers[14]: LDL cholesterol reductions of 15-20% observed with GLP3 Triglyceride reductions of 20-30% documented across studies Improved HDL cholesterol levels in some study populations Potential PCSK9 degradation effects through glucagon receptor activation Blood Pressure and Heart Rate Effects Cardiovascular monitoring in clinical trials revealed consistent patterns[15]: Systolic blood pressure reductions of 5-10 mmHg observed with weight loss Diastolic pressure improvements of 3-5 mmHg documented Dose-dependent heart rate increases (5-10 bpm) that peaked at 24 weeks then declined Heart rate changes similar to other GLP-1 receptor agonists Hepatic Steatosis and Liver Health Research Liver Fat Reduction Studies Research in metabolic dysfunction-associated steatotic liver disease (MASLD) models showed remarkable effects[16]: GLP3 achieved 82% relative liver fat reduction after 48 weeks in phase 2a MASLD trials Over 85% of participants achieved resolution of MASLD (liver fat below 5%) Improvements in liver enzymes (ALT, AST) and fibrosis biomarkers documented Potential anti-fibrotic effects through multiple pathway modulation The glucagon receptor component appears particularly relevant for liver fat reduction, as the liver is rich in glucagon receptors but lacks GLP-1 receptors

The researchers showed that senescent Leydig cell accumulation is a driver of age-related testosterone decline, and that targeted elimination of these cells with FOXO4-DRI restored endocrine function